KIRKLAND 4 – Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that Health Canada has authorized the KP.2 variant adapted COMIRNATY® COVID-19 vaccine for ages 6 months and older. The updated COMIRNATY® vaccine targets the Omicron KP.2 variant, one of the most recently circulating SARS-CoV-2 lineages. The adapted COVID-19 vaccine will be available in Canada as a single dose for individuals 5 …
MAINZ – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech’s clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy approaches. …
MAINZ — Pfizer Japan Inc. and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced conclusion of an agreement between the Japanese government and Pfizer Japan Inc. to supply an additional 10 million doses of the Omicron XBB.1.5-adapted COVID-19 vaccine (COMIRNATY Omicron XBB.1.5) for the special vaccination program in Japan which started this autumn. The vaccine doses to be supplied based on this agreement will be …
